| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
FAK-IN-7 targets focal adhesion kinase (FAK), a non-receptor tyrosine kinase involved in cell adhesion, migration, survival, and proliferation. FAK is overexpressed or hyperactivated in many cancers and contributes to tumor progression, invasion, and metastasis. By inhibiting FAK with an IC50 of 11.72 µM, FAK-IN-7 disrupts FAK-mediated signaling pathways, reducing tumor cell adhesion, migration, and survival. The compound's anti-proliferative activity supports its potential in cancer research.
|
|---|---|
| ln Vitro |
MCF-7 and B16-F10 cell growth is inhibited by FAK-IN-7 (0-10 µM; 48 hours) [1].
In vitro, FAK-IN-7 shows FAK inhibition with an IC50 of 11.72 µM. It has good anti-proliferative activity against cancer cells. The compound can be used to study the role of FAK in cancer cell adhesion, migration, and survival. Its activity against breast and ovarian cancer cells has been investigated, and it may enhance the immune system's ability to target cancer cells. Further studies would be needed to fully characterize its cellular effects. |
| ln Vivo |
In vivo, FAK-IN-7 has potential for treating various cancers, including breast and ovarian cancer. By inhibiting FAK, the compound may reduce tumor growth and enhance immune-mediated tumor cell killing. However, specific in vivo efficacy data for FAK-IN-7 have not been detailed in the available literature. Preclinical studies in xenograft models would be required to assess its anti-tumor efficacy, tolerability, and pharmacokinetic properties.
|
| Enzyme Assay |
For in vitro kinase assays, recombinant FAK protein is incubated with a peptide substrate and ATP in kinase assay buffer. The test compound is added at various concentrations (typically 0.1-100 µM). Kinase activity is measured using radioactive ATP incorporation, followed by filter binding and scintillation counting, or using non-radioactive methods such as luminescent ADP detection assays. IC50 values are calculated by fitting dose-response curves.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: MCF-7 and B16-F10 Cell Tested Concentrations: 0-10 µM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated anti-proliferative activity against MCF-7 and B16-F10 cells with IC50 values of 3.57 and 3.52 µM respectively. For cell proliferation assays, cancer cell lines (such as breast or ovarian cancer cells) are seeded in 96-well plates and treated with FAK-IN-7 at concentrations ranging from 0.1-100 µM for 48-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. IC50 values are calculated from dose-response curves. Cell migration and invasion assays (such as wound healing or transwell assays) can be performed to assess the functional consequences of FAK inhibition on cell motility. |
| Animal Protocol |
For in vivo efficacy studies, immunodeficient mice would be implanted with breast or ovarian cancer cells. When tumors reach a predetermined size, mice would be randomized to receive FAK-IN-7 via appropriate routes at doses determined from pharmacokinetic studies. Tumor volumes would be measured twice weekly. At study endpoint, tumors would be collected for histological analysis, immunohistochemistry for FAK phosphorylation, and assessment of immune cell infiltration to evaluate the compound's effects on tumor growth and immune response.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of FAK-IN-7 have been partially characterized. The compound is soluble in DMSO at 10 mg/mL (33.86 mM) with ultrasonic warming to 60°C. Storage is recommended at -20°C. Further detailed PK parameters including half-life, bioavailability, and tissue distribution would be required for in vivo studies. The compound's molecular weight of 295.36 g/mol suggests potential for drug-like properties.
|
| Toxicity/Toxicokinetics |
Toxicological data for FAK-IN-7 have not been reported in the available literature. As a research compound, it is intended for laboratory use only and is not for human or veterinary use. Standard safety precautions should be followed when handling this compound. Comprehensive toxicology studies would be required before any clinical development.
|
| References | |
| Additional Infomation |
FAK-IN-7 (compound 5r) is a FAK inhibitor with an IC50 of 11.72 µM. It has good anti-proliferative activity and can be used in cancer research. The compound has potential applications in treating breast and ovarian cancer by reducing tumor growth and enhancing anti-tumor immune responses. FAK-IN-7 is a research tool for studying FAK biology and is not approved for clinical use.
|
| Molecular Formula |
C16H13N3OS
|
|---|---|
| Molecular Weight |
295.359
|
| Exact Mass |
295.077
|
| CAS # |
19948-85-7
|
| PubChem CID |
569511
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C2SC(NC(=O)C3=CC=CC=C3)=NN=2)C=C1
|
| InChi Key |
SIHYHKOFZPWMHZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13N3OS/c1-11-7-9-13(10-8-11)15-18-19-16(21-15)17-14(20)12-5-3-2-4-6-12/h2-10H,1H3,(H,17,19,20)
|
| Chemical Name |
N-[5-(4-methylphenyl)-1,3,4-thiadiazol-2-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~33.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3857 mL | 16.9285 mL | 33.8570 mL | |
| 5 mM | 0.6771 mL | 3.3857 mL | 6.7714 mL | |
| 10 mM | 0.3386 mL | 1.6928 mL | 3.3857 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
